Sanchez-Martinez Vanessa, Romero-Rubio Dolores, Abad-Perez Maria Jose, Descalzo-Cabades Maria Amparo, Alonso-Gutierrez Sofia, Salazar-Fraile Jose, Montagud Vicente, Facila Lorenzo
Department of Nursing, Faculty of Nursing and Chiropody, University of Valencia, Valencia, Spain.
Community Mental Health Centre Pere Bonfill, Valencia, Spain.
Endocr Metab Immune Disord Drug Targets. 2018;18(4):379-387. doi: 10.2174/1871530317666171120151201.
People with schizophrenia and other severe mental disorders have an increased mortality mainly attributed to natural causes, specifically cardiovascular disease and cancer. The metabolic syndrome and the Framingham Risk Score are epidemiologic tools related to long-term cardiovascular disease risk and they are increased in people with severe mental disorders. This increase has been attributed both to the disorder itself and to the use of antipsychotic drugs.
To quantify the cardiovascular risk in a group of people treated with long-acting injectable antipsychotics.
This is a cross-sectional study developed in an outpatient mental health clinic in which the prevalence of metabolic syndrome was estimated and the cardiovascular risk was measured using the Framingham Risk Score. All the analyses were separated by gender.
130 people (81 men) were recruited. According to the International Diabetes Federation criteria, 60 participants (46,2%) had metabolic syndrome. The individual criterion most often met in both genders was obesity. The mean Framingham Risk Score for the sample was moderate, 7,7 (SD: 6,3). For women, the risk was lower (mean 5,7, SD: 4,9) than for men (mean=9, SD: 6,7). There were no significant differences in the prevalence of metabolic syndrome and Framingham Risk Scores by longacting injectable antipsychotic or years of treatment.
The prevalence of metabolic syndrome and the cardiovascular risk are high in people with psychosis treated with long acting injectable antipsychotics. To better address this vulnerability, the recommendations involve both behavioral and pharmacological interventions.
精神分裂症和其他严重精神障碍患者的死亡率增加，主要归因于自然原因，特别是心血管疾病和癌症。代谢综合征和弗雷明汉风险评分是与长期心血管疾病风险相关的流行病学工具，在严重精神障碍患者中有所增加。这种增加既归因于疾病本身，也归因于抗精神病药物的使用。
量化一组接受长效注射用抗精神病药物治疗的人群的心血管风险。
这是一项在门诊心理健康诊所开展的横断面研究，其中估计了代谢综合征的患病率，并使用弗雷明汉风险评分测量心血管风险。所有分析均按性别分开。
招募了130人（81名男性）。根据国际糖尿病联盟标准，60名参与者（46.2%）患有代谢综合征。在两性中最常达到的个体标准是肥胖。样本的平均弗雷明汉风险评分为中度，7.7（标准差：6.3）。女性的风险（平均5.7，标准差：4.9）低于男性（平均=9，标准差：6.7）。代谢综合征的患病率和弗雷明汉风险评分在长效注射用抗精神病药物或治疗年限方面没有显著差异。
接受长效注射用抗精神病药物治疗的精神病患者中代谢综合征的患病率和心血管风险很高。为了更好地应对这种易感性，建议包括行为和药物干预。
